10X Genomics
Logotype for 10X Genomics Inc

10X Genomics (TXG) investor relations material

10X Genomics Q4 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for 10X Genomics Inc
Q4 2025 earnings summary12 Feb, 2026

Executive summary

  • Q4 2025 revenue reached $166 million, up 1% year-over-year and exceeding guidance; full-year revenue was $599 million excluding $44 million from patent litigation settlements, or $642.8 million including them.

  • Operating environment remained challenging with subdued customer spending and constrained capital equipment purchases, but underlying demand for solutions remained solid.

  • Single-cell consumables volumes grew at a double-digit rate each quarter, driven by adoption of lower-cost products like Flex and on-chip multiplexing.

  • Strategic partnerships and collaborations were established with Cancer Research Institute, PharosAI, Dana-Farber Cancer Institute, Brigham & Women's Hospital, and others to advance AI-driven and translational research.

  • Cash balance increased by over $130 million year-over-year, ending 2025 at $523.4 million.

Financial highlights

  • Q4 revenue grew 1% year-over-year, surpassing the high end of guidance.

  • Total consumables revenue for 2025 was $507.2 million, up from $493.4 million in 2024; instrument revenue declined to $56.8 million from $92.7 million.

  • Q4 gross margin was 68%, up from 67% the prior year; full-year gross margin was 69%.

  • Q4 operating expenses decreased 18% year-over-year to $132.6 million, mainly due to lower legal and personnel costs and a $49.9 million litigation settlement gain.

  • Q4 operating loss was $19.5 million, a significant improvement from $49.8 million in Q4 2024; full-year operating loss narrowed to $61.0 million from $194.6 million in 2024.

Outlook and guidance

  • 2026 revenue expected between $600 million and $625 million, representing 0%-4% growth over 2025, excluding non-recurring 2025 license and royalty revenue.

  • Double-digit growth anticipated for single-cell consumables reactions and spatial consumables revenue.

  • CapEx funding expected to remain constrained, continuing to pressure instrument revenue.

  • Q1 2026 revenue projected to be a higher percentage of full-year revenue due to late Q4 orders shipped in January.

  • Continued focus on cost discipline and operating efficiency expected to further strengthen financial profile in 2026.

Flex Apex role in AI-driven studies
Diagnostics market entry strategy
Chromium consumables: volume vs. price impact
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next 10X Genomics earnings date

Logotype for 10X Genomics Inc
Q1 20267 May, 2026
10X Genomics
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next 10X Genomics earnings date

Logotype for 10X Genomics Inc
Q1 20267 May, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

10x Genomics, Inc. is a life science technology company that develops and sells instruments, consumables, and software for analyzing biological systems. The Company's proprietary sequencing technology establishes the framework for interrogating vast amounts of genetic information from thousands of samples at a cost and speed that rivals other sequencing methodology. Its products can obtain billions of sequence reads within a few days to weeks in order to support complex experiments and provide high-quality results that accurately reflect genetic variation across the human genome.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage